ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience

“We started Replicate to build a best-in-class srRNA platform from scratch—to pursue our vision of a better way to make srRNAs that we are convinced can solve life-threatening medical problems, from drug resistance in cancer to autoimmune and inflammatory disorders and more.” Nathaniel Wang, PhD Replicate Bioscience CEO NEW YORK and SAN DIEGO, Sept. 8, 2021 /PRNewswire/ — ATP, … Continue reading ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience